DOAC in Patients with Child a or B Liver Cirrhosis
ConditionLiver Cirrhosis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire Vaudois
About this trial
The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with Child A or B liver cirrhosis (LC). The primary objective of this study is to verify the ability of apixaban and edoxaban to decrease in vivo thrombin generation in LC patients.
Participants will be randomly assigned to either apixaban (Eliquis®) or edoxaban (Lixiana®) at a therapeutic dosage for 7 consecutive days.
The results of this investigation will contribute to designing a prospective multicentre interventional study to investigate the efficacy of DOAC to improve clinical outcomes in patients with LC
Eligibility criteria
Qualifiers
Age 18 years or older
Patient with previously diagnosed liver cirrhosis Child A or B
Written informed consent
Disqualifiers
Pregnancy
Oesophageal varices with grade superior to 1 or with red signs
Active ulcer disease of the gastrointestinal tract
History of haemorrhagic stroke
Trial design
Treatments tested in this trial
- Apixaban 5 MG [Eliquis]
- Edoxaban 60 MG [Lixiana]
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov